Literature DB >> 7612189

Selective recognition of the activated form of transcription factor NF-kappa B by a monoclonal antibody.

C Kaltschmidt1, B Kaltschmidt, T Henkel, H Stockinger, P A Baeuerle.   

Abstract

Transcription factor NF-kappa B is a central regulator of inflammatory, immune and acute phase reactions. It rapidly initiates the transcription of a wide variety of target genes in response to various pathogenic stimuli. Because NF-kappa B is predominantly controlled at a posttranscriptional level through association with the inhibitory I kappa B subunits, its activation cannot be monitored directly at a cellular level by means of detecting new mRNA or protein synthesis. In this study, we describe a monoclonal antibody, designated alpha-p65MAb, that recognizes an epitope which includes the nuclear location signal (NLS) of p65, the DNA binding subunit mainly responsible for the strong gene-inductory potential of NF-kappa B. alpha-p65MAb recognized human and rodent p65 only when I kappa B alpha was not bound to p65. Thus, the IgG3 selectively stained the activated, nuclear form of NF-kappa B in cultured cells. Unlike I kappa B, the MAb and its Fab fragments did not inhibit the DNA binding activity of NF-kappa B in mobility shift assays. We show that alpha-p65MAb is suitable to study the activation state of NF-kappa B in cryosections of tissues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612189     DOI: 10.1515/bchm3.1995.376.1.9

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  24 in total

1.  Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis.

Authors:  B Kaltschmidt; M Uherek; H Wellmann; B Volk; C Kaltschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway.

Authors:  Li Zhang; Michael Chopp; Xianshuang Liu; Hua Teng; Tao Tang; Haifa Kassis; Zheng Gang Zhang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

3.  An investigation of the specificity of research antibodies against NF-κB-subunit p65.

Authors:  Carsten Slotta; Janine Müller; Loan Tran; Stefan Hauser; Darius Widera; Barbara Kaltschmidt; Christian Kaltschmidt
Journal:  J Histochem Cytochem       Date:  2013-11-19       Impact factor: 2.479

4.  In situ glomerular expression of activated NF-kappaB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy.

Authors:  Ling Zheng; Raja Sinniah; Stephen I-Hong Hsu
Journal:  Virchows Arch       Date:  2005-10-05       Impact factor: 4.064

5.  Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke.

Authors:  Longfei Jia; Michael Chopp; Li Zhang; Mei Lu; Zhenggang Zhang
Journal:  Stroke       Date:  2010-07-29       Impact factor: 7.914

6.  Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras.

Authors:  A Brack; H L Rittner; B R Younge; C Kaltschmidt; C M Weyand; J J Goronzy
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

Review 7.  Exploiting our knowledge of NF-kappaB signaling for the treatment of mammary cancer.

Authors:  Michael C Haffner; Chiara Berlato; Wolfgang Doppler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

8.  Pathogenic role of NF-kappaB activation in tubulointerstitial inflammatory lesions in human lupus nephritis.

Authors:  Ling Zheng; Raja Sinniah; Stephen I-Hong Hsu
Journal:  J Histochem Cytochem       Date:  2008-02-18       Impact factor: 2.479

9.  The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.

Authors:  Vanessa Almendro; Elisabet Ametller; Susana García-Recio; Olga Collazo; Ignasi Casas; Josep M Augé; Joan Maurel; Pedro Gascón
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

10.  Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.

Authors:  Li Zhang; Michael Chopp; Hua Teng; Guangliang Ding; Quan Jiang; Xiao Ping Yang; Nour Eddine Rhaleb; Zheng Gang Zhang
Journal:  Stroke       Date:  2014-02-18       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.